摘要 |
The present invention provides targeted treatment to subjects suffering from Frontotemporal lobar degeneration through use of FTLD targeted agents, as described in the present invention. In particular, the FTLD targeted agents provided herein demonstrate high brain penetration, which decreases risk issues associated with peripheral administration. Furthermore, the FTLD targeted agents of the present invention, when administered to a subject selected for treatment based on the results of a FTLD diagnostic assay, offer targeted treatment of FTLD. |